新股消息 | 易慕峰生物递表港交所

Group 1 - The core viewpoint of the article is that Shenzhen Yimufeng Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as its sole sponsor [1] - Yimufeng Biotechnology is described as a global leader in innovative cell therapy, focusing on its core product IMC002, which is a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate [1] - The IMC002 therapy is currently in a critical clinical phase (Phase III clinical trial) and is noted to be the second in clinical progress globally among solid tumor CAR-T therapy candidates [1]